On the data side, the Lau phase 2 obesity trial showed Cagrilintide monotherapy producing dose-related weight loss, reaching close to 10.8 percent at the top dose over roughly 26 weeks, against about 3 percent on placebo
PubMed Kaux J-F, et al
Hair Effects On scalp and hair, GHK-Cu shows promise in revitalizing follicles
Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Form & Stability Lyophilized peptide for research purposes Store refrigerated (28 C) and protect from light Reconstitute under sterile conditions before use Disclaimer This compound is intended for laboratory and scientific research only
There are few complaints of mild skin reactions which may have been arising from the use of the enjoyed benefits